MedPath

Acelyrin

Acelyrin logo
🇺🇸United States
Ownership
Public
Established
2020-01-01
Employees
130
Market Cap
$503M
Website
http://www.acelyrin.com
Introduction

ACELYRIN, Inc. operates as a biopharma company. It engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company was founded by Shao-Lee Lin on July 27, 2020 and is headquartered in Agoura Hills, CA.

Clinical Trials
Related News

Hidradenitis Suppurativa Study of Izokibep

Phase 3
Active, not recruiting
Conditions
Hidradenitis Suppurativa
Interventions
Drug: Placebo
Drug: Izokibep
First Posted Date
2023-06-15
Last Posted Date
2024-12-04
Lead Sponsor
ACELYRIN Inc.
Target Recruit Count
258
Registration Number
NCT05905783
Locations
🇪🇸

Clinical Research Site, Madrid, Spain

Efficacy and Safety of Lonigutamab in Subjects With Thyroid Eye Disease (TED)

Phase 1
Recruiting
Conditions
Thyroid Eye Disease
Interventions
Drug: lonigutamab
Drug: Placebo
First Posted Date
2023-01-13
Last Posted Date
2024-11-25
Lead Sponsor
ACELYRIN Inc.
Target Recruit Count
38
Registration Number
NCT05683496
Locations
🇦🇺

Clinical Research Site, Nedlands, Western Australia, Australia

Psoriatic Arthritis Study of Izokibep

Phase 2
Terminated
Conditions
Psoriatic Arthritis
Interventions
Drug: Izokibep
Drug: Placebo to izokibep
First Posted Date
2022-11-21
Last Posted Date
2024-11-27
Lead Sponsor
ACELYRIN Inc.
Target Recruit Count
351
Registration Number
NCT05623345
Locations
🇪🇸

Clinical Research Site, Sevilla, Spain

🇭🇺

Clinical Research Site (003), Budapest, Hungary

Phase 2b Pivotal Study of Izokibep in Non-infectious, Intermediate-, Posterior- or Pan-uveitis

Phase 2
Active, not recruiting
Conditions
Uveitis
Interventions
Drug: Placebo
Drug: Izokibep
First Posted Date
2022-05-20
Last Posted Date
2024-12-17
Lead Sponsor
ACELYRIN Inc.
Target Recruit Count
96
Registration Number
NCT05384249
Locations
🇪🇸

Clinical Research Site, Zaragoza, Spain

🇪🇸

Clinical Research Site (4007), Santiago De Compostela, Spain

🇪🇸

Clinical Research Site (4008), Santiago De Compostela, Spain

Hidradenitis Suppurativa Phase 2b Pivotal Study of Izokibep

Phase 2
Completed
Conditions
Hidradenitis Suppurativa
Interventions
Drug: Izokibep
Drug: Placebo to izokibep
First Posted Date
2022-05-02
Last Posted Date
2024-03-08
Lead Sponsor
ACELYRIN Inc.
Target Recruit Count
176
Registration Number
NCT05355805
Locations
🇪🇸

Clinical Research Site, Barcelona, Spain

A Study to Investigate Efficacy, Tolerability and Safety of ABY-035 in Patients With Active Psoriatic Arthritis

Phase 2
Completed
Conditions
Psoriatic Arthritis
Interventions
Biological: Placebo
Biological: ABY-035
First Posted Date
2021-01-19
Last Posted Date
2024-02-09
Lead Sponsor
ACELYRIN Inc.
Target Recruit Count
129
Registration Number
NCT04713072
Locations
🇨🇿

Revmatologický ústav, Praha, Czechia

🇦🇹

Medizinische Universität Innsbruck/Tirol Kliniken GmbH Universitätsklinik für Innere Medizin II, Innsbruck, Austria

🇪🇸

Complejo Hospitalario Universitario de A Coruña, Coruña, Spain

and more 29 locations

A Trial of the Efficacy and Safety of Izokibep in the Treatment of Non-anterior Uveitis

Phase 2
Completed
Conditions
Uveitis
Interventions
Drug: Izokibep
Drug: Prednisone/Prednisolone
First Posted Date
2021-01-13
Last Posted Date
2024-02-12
Lead Sponsor
ACELYRIN Inc.
Target Recruit Count
7
Registration Number
NCT04706741
Locations
🇺🇸

Research Site, Plano, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy